BNP Paribas Financial Markets
ADMA icon

BNP Paribas Financial Markets’s ADMA Biologics ADMA Stock Holding History

BNP Paribas Financial Markets’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Sell
1,454,295
-451,177
-24% -$4.11M ﹤0.01% 1523
2026
Q1 		$17.2M Buy
1,905,472
+764,366
+67% +$12.1M 0.01% 1262
2025
Q4 		$20.8M Buy
1,141,106
+1,091,241
+2,188% +$18.4M 0.01% 1153
2025
Q3 		$731K Buy
49,865
+18,564
+59% +$318K ﹤0.01% 3349
2025
Q2 		$570K Sell
31,301
-57,509
-65% -$1.17M ﹤0.01% 3248
2025
Q1 		$1.76M Buy
88,810
+12,038
+16% +$208K ﹤0.01% 2434
2024
Q4 		$1.32M Sell
76,772
-674,016
-90% -$12.7M ﹤0.01% 2643
2024
Q3 		$15M Buy
750,788
+85,250
+13% +$1.33M 0.01% 991
2024
Q2 		$7.44M Sell
665,538
-67,382
-9% -$565K 0.01% 1227
2024
Q1 		$4.84M Buy
732,920
+442,315
+152% +$2.42M ﹤0.01% 1477
2023
Q4 		$1.31M Buy
290,605
+96,653
+50% +$358K ﹤0.01% 2223
2023
Q3 		$694K Buy
193,952
+27,995
+17% +$108K ﹤0.01% 2540
2023
Q2 		$612K Sell
165,957
-255,759
-61% -$948K ﹤0.01% 2481
2023
Q1 		$1.4M Buy
421,716
+235,185
+126% +$813K ﹤0.01% 2091
2022
Q4 		$724K Sell
186,531
-53,122
-22% -$164K ﹤0.01% 2360
2022
Q3 		$582K Buy
239,653
+197,752
+472% +$474K ﹤0.01% 2880
2022
Q2 		$83K Buy
41,901
+40,717
+3,439% +$80.1K ﹤0.01% 3413
2022
Q1 		$2.17K Hold
1,184
– – ﹤0.01% 3900
2021
Q4 		$1.67K Sell
1,184
-204
-15% -$268 ﹤0.01% 4013
2021
Q3 		$1.57K Sell
1,388
-185
-12% -$259 ﹤0.01% 3831
2021
Q2 		$2.52K Sell
1,573
-8,214
-84% -$14.5K ﹤0.01% 3857
2021
Q1 		$17.2K Sell
9,787
-3,163
-24% -$7.24K ﹤0.01% 3782
2020
Q4 		$25.3K Sell
12,950
-1,478
-10% -$3.11K ﹤0.01% 3798
2020
Q3 		$34.5K Buy
14,428
+11,482
+390% +$31.5K ﹤0.01% 3632
2020
Q2 		$8.63K Sell
2,946
-18,122
-86% -$52.1K ﹤0.01% 3765
2020
Q1 		$60.7K Buy
21,068
+15,219
+260% +$52.6K ﹤0.01% 3450
2019
Q4 		$23.4K Sell
5,849
-521
-8% -$2.27K ﹤0.01% 3953
2019
Q3 		$28.3K Buy
6,370
+3,981
+167% +$16.6K ﹤0.01% 3788
2019
Q2 		$9.24K Sell
2,389
-1,726
-42% -$7.62K ﹤0.01% 4115
2019
Q1 		$15.6K Buy
+4,115
New +$14.5K ﹤0.01% 3956

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BNP Paribas Financial Markets's ADMA Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its ADMA Biologics (ADMA) stake by 24% in Q2 2026, selling an estimated $4.11M and leaving 1,454,295 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

BNP Paribas Financial Markets first reported a position in ADMA in Q1 2019 and has held it in 30 quarters since. The position peaked at $20.8M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • BNP Paribas Financial Markets held 1,454,295 shares of ADMA Biologics worth $12.2M as of Q2 2026.
  • BNP Paribas Financial Markets sold 451,177 ADMA Biologics shares in Q2 2026, an estimated $4.11M.
  • ADMA Biologics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1523 holding.
  • BNP Paribas Financial Markets first reported a position in ADMA Biologics in Q1 2019 and has held it in 30 quarters since.
  • BNP Paribas Financial Markets's ADMA Biologics position peaked at $20.8M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.